Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quoin Pharmaceuticals Ltd. (QNRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, and its filings offer detailed insight into clinical development plans, financing structures, governance decisions and risk factors relevant to investors.
Among the most informative documents for QNRX are its periodic reports and current reports on Form 8-K. Recent 8-K filings describe key events such as private placement financings involving American Depositary Shares, pre-funded warrants and multiple series of warrants tied to milestones for the lead asset, QRX003, including pivotal trial outcomes and potential FDA approval. Other 8-Ks outline regulatory milestones, including Orphan Drug Designation and Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome, as well as corporate actions like equity incentive plan approvals, changes in executive leadership and amendments to the company’s articles of association.
For users interested in the clinical and regulatory trajectory of Quoin’s programs, filings referenced to press releases detail the status of late-stage pivotal trials for QRX003, investigator-led pediatric studies and the development of topical rapamycin delivery technologies targeting microcystic lymphatic malformations and venous malformations. These documents also include the company’s cautionary statements about forward-looking information, highlighting uncertainties around clinical trial results, regulatory approvals, funding needs and operational risks.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of each filing in clear language. Users can quickly understand the core points of complex agreements, equity incentive plans, financing terms and clinical disclosures without reading every page of the original document. In addition, the filings page makes it easier to monitor governance items such as compensation policies, lock-up agreements and shareholder meeting results, all of which can influence the risk–reward profile of QNRX for market participants.
Quoin Pharmaceuticals (QNRX) director Dennis Langer reported a purchase of 15,152 ADS on 10/14/2025 at a combined price of $8.49 per ADS in a private placement. Each ADS was purchased together with one Series H, Series I, Series J, and Series K warrant to buy one ADS.
The filing lists warrants for 15,152 ADS each with exercise prices of $9.075 (Series H), $10.3125 (Series I), and $12.375 (Series J and K). The warrants were exercisable immediately, subject to a beneficial ownership cap, and include milestone-based expirations tied to FDA-related events or a Priority Review Voucher sale, or five years from the closing date, whichever occurs earlier as specified for each series.
Following the reported transactions, Langer beneficially owned 15,153 ADS directly. Each ADS represents 35 ordinary shares of the company.
Quoin Pharmaceuticals, Ltd. reported an initial beneficial ownership filing by Sally Bridget Lawlor, identifying her as Chief Financial Officer and a director. The filing reports ownership of 440 ADSs held directly; each ADS represents 35 ordinary shares. The transaction date triggering the filing is
Quoin Pharmaceuticals Ltd. filed an S-8 registration to register securities related to its employee benefit program. The filing incorporates the companys Form 10-K for the year ended December 31, 2024 and subsequent Form 10-Qs and Form 8-Ks through August 27, 2025. Exhibits include amended articles, a deposit agreement for ADSs, a 2025 Equity Incentive Plan (Exhibit 4.4), legal opinion and accountant consents. The filing supplies standard indemnification and insurance terms for officers and directors under Israeli law.
Quoin Pharmaceuticals reported the separation of an executive under a Separation Agreement that provides three key elements: a cash payment of $433,620 to be delivered in equal bi-weekly installments in lieu of 12 months' notice; a $108,405 bonus for the 2024 financial year to be paid in a lump sum on the one-year anniversary of the Separation Agreement's effective date; and an amendment to outstanding vested non-qualified stock options that extends the post-termination exercise window from 90 days to 1 year and 9 months. The filing is signed by Dr. Michael Myers, Chief Executive Officer, and includes an Inline XBRL cover page reference.
Quoin Pharmaceuticals Ltd. filed a Form S-8 to register securities for its American employee benefit plan. The submission references its Form 10-K for the year ended December 31, 2024, and subsequent Form 10-Qs and multiple Form 8-Ks filed between January and August 2025. The filing includes customary indemnification and insurance provisions for officers and directors, an exhibit list (legal opinion, auditor consent, power of attorney, filing fee table), and is signed by Dr. Michael Myers as CEO and authorized U.S. representative on August 25, 2025.
Quoin Pharmaceuticals director Natalie Ee Mun Leong reported an award of a share option on 08/21/2025 exercisable for 4,105 American Depositary Shares (ADSs) representing underlying ordinary shares. The option’s stated exercise price is $9.07 per ADS. The grant was approved by the Compensation Committee and Board on May 29, 2025 and was subsequently approved by shareholders on August 21, 2025. The option vests over four annual installments: 20% on each of May 29, 2026, 2027 and 2028, and 40% on May 29, 2029.
Anthony James Culverwell, a director of Quoin Pharmaceuticals, Ltd. (QNRX), was granted a stock option on 08/21/2025 covering 13,682 American Depositary Shares (ADSs) with an exercise price of $9.07 per ADS. Each ADS represents 35 ordinary shares, so the option covers the ADS-denominated equivalent of the underlying ordinary shares.
The option was approved by the Compensation Committee and Board on 05/29/2025 and became effective upon shareholder approval on 08/21/2025. The award vests over four annual installments: 20% vesting on each of 05/29/2026, 05/29/2027 and 05/29/2028, and 40% vesting on 05/29/2029. The reported ownership following the grant is 13,682 ADSs, held directly.
Quoin Pharmaceuticals, Ltd. (QNRX) director Dennis Langer was granted a share option to purchase 13,682 ADSs on August 21, 2025, as reported on Form 4 filed August 25, 2025. The option is stated in ADS terms with an exercise price of $9.07 per ADS; each ADS represents 35 ordinary shares. The grant was approved by the Compensation Committee and Board on May 29, 2025, subject to shareholder approval, and shareholders approved it on August 21, 2025. The option vests in four annual installments: 20% on each May 29 of 2026, 2027 and 2028, and 40% on May 29, 2029.
Quoin Pharmaceuticals Ltd. furnished a Form 8-K reporting corporate governance and personnel items. The filing lists several governance topics including the submission of matters to a vote of security holders, a material modification to rights of security holders, departures and elections of directors or certain officers, and compensatory arrangements for officers. The document discloses one specific executive term: Ms. Lawlor will be entitled to 28 days' annual leave in each calendar year (in addition to statutory public holidays). The Form 8-K was executed by the company's Chief Executive Officer.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
